Biotech
Companies with platform underlying technologies that have or could create multiple drug candidates
Broad applicability and de-risk profile have positioned biotech platforms as great acquisition candidates
Platform technology addressing key unmet medical needs
Digital Health
There is an increasing shift from B2B-only offerings to direct-to-consumer (D2C), and B2B-and-D2C mixed offerings
Investors are doubling-down on their investments, prolonging the strong tailwind due to the COVID-19 pandemic
Medical Technology
(Medtech)
There has been a recent spike in Medtech VC investment amidst the COVID-19 pandemic
Recent increased investment in Telehealth, Omics, and AI
Constantly in the look out for superior technology with clear potential to scale up
